<DOC>
	<DOCNO>NCT00295867</DOCNO>
	<brief_summary>RATIONALE : Zoledronate may delay prevent bone marrow metastases patient breast cancer . PURPOSE : This phase II trial study well zoledronate work treat bone marrow micrometastases woman stage I , stage II , stage III breast cancer .</brief_summary>
	<brief_title>Zoledronate Treating Bone Marrow Micrometastases Women With Stage I , Stage II , Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response bone marrow micrometastases , measure immunocytochemistry/flow cytometry ( IC/FC ) , 2 year treatment zoledronate woman stage I-III breast cancer . Secondary - Evaluate effect zoledronate bone osteoclast activation marker , n-telopeptide , patient . - Evaluate incidence distant recurrence high-risk woman early-stage breast cancer bone marrow micrometastases receive adjuvant zoledronate . OUTLINE : This pilot study . Patients receive zoledronate IV 15 minute month 2 year absence disease progression unacceptable toxicity . After completion study treatment , patient follow every 6 month . PROJECTED ACCRUAL : A total 35 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIII breast cancer Bone marrow aspirate positive ( immunocytochemistry/flow cytometry [ IC/FC ] assay ) diagnosis OR prior adjuvant chemotherapy* More 4 micrometastases/mL NOTE : *If patient receive adjuvant chemotherapy , must complete start study treatment Hormone receptor status specify PATIENT CHARACTERISTICS : Female Menopausal status specify Karnofsky performance status ≥ 90 % Creatinine normal Creatinine clearance ≥ 50 mL/min Total bilirubin , alkaline phosphatase , AST normal No history allergy bisphosphonates Acute phase reaction consider allergic reaction No history renal insufficiency No significant medical condition may interfere study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics Prior surgery neoadjuvant chemotherapy hormonal therapy allow No concurrent bisphosphonate therapy , include oral bisphosphonates No concurrent cytotoxic anticancer therapy No concurrent investigational drug Concurrent hormonal therapy radiotherapy allow</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>stage I breast cancer</keyword>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
</DOC>